scholarly journals POS-531 LIPID PROFILE AND CARDIOVASCULAR RISK IN CHRONIC HEMODIALYSIS PATIENTS

2021 ◽  
Vol 6 (4) ◽  
pp. S231
Author(s):  
I. Nasri ◽  
M. Khadhar ◽  
S. Bouassida ◽  
R. Lazzez ◽  
S. Agrebi ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis

scholarly journals Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple

2020 ◽  
Vol 9 (3) ◽  
pp. 629 ◽  
Author(s):  
Mariadelina Simeoni ◽  
Alessandra F. Perna ◽  
Giorgio Fuiano
Keyword(s):  
Clinical Trials ◽  
Cardiovascular Risk ◽  
Mortality Rate ◽  
Secondary Hyperparathyroidism ◽  
Major Complication ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Maintenance Hemodialysis ◽  
High Cardiovascular Risk ◽  
High Prevalence

Secondary hyperparathyroidism (SHPTH) is a major complication in patients on maintenance hemodialysis burdened with high cardiovascular risk. Hypertension is also a high prevalence complication contributing to an increase in the mortality rate in hemodialysis patients. A possible association between SHPTH and hypertension has been widely reported in the literature and several pathogenetic mechanisms have been described. There is evidence that the decrease of plasma iPTH levels are correlated with hypertension correction in hemodialysis patients undergoing parathyroidectomy and oral calcimimetics administration. We have observed a similar behaviour also in a patient on chronic hemodialysis treated with Etelcalcetide. Even if this is an isolated observation, it could stimulate future investigation, possibly in dedicated clinical trials.

Calcium Acetate/Magnesium Carbonate and Cardiovascular Risk Factors in Chronic Hemodialysis Patients

Nephron ◽  
2016 ◽  
Vol 132 (4) ◽  
pp. 317-326 ◽  
Author(s):  
Patrícia João Matias ◽  
Cristina Jorge ◽  
Ana Azevedo ◽  
Ivo Laranjinha ◽  
David Navarro ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Magnesium Carbonate ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Calcium Acetate

scholarly journals SP733CHANGES IN BIOIMPEDANCE ANALYSIS MEASURES IN CHRONIC HEMODIALYSIS PATIENTS DURING ONE YEAR

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii619-iii620
Author(s):  
Ruta Vaiciuniene ◽  
Irmante Stramaityte ◽  
Edita Ziginskiene ◽  
Vytautas Kuzminskis ◽  
Inga Arune Bumblyte
Keyword(s):  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Bioimpedance Analysis ◽  
One Year

Physical activity patterns in chronic hemodialysis patients: Comparison of dialysis and nondialysis days

2005 ◽  
Vol 15 (2) ◽  
pp. 217-224 ◽  
Author(s):  
Karen M. Majchrzak ◽  
Lara B. Pupim ◽  
Kong Chen ◽  
Cathi J. Martin ◽  
Sheila Gaffney ◽  
...  
Keyword(s):  
Physical Activity ◽  
Activity Patterns ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Physical Activity Patterns

scholarly journals Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Andrea Giacomelli ◽  
Federico Conti ◽  
Laura Pezzati ◽  
Letizia Oreni ◽  
Anna Lisa Ridolfo ◽  
...  
Keyword(s):  
Body Weight ◽  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Risk Score ◽  
Rank Test ◽  
People Living With Hiv ◽  
Cholesterol Levels ◽  
Signed Rank Test ◽  
Living With Hiv

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in a cohort of people living with HIV/AIDS (PLWH) under effective ART. Methods All PLWH aged above 18 years on antiretroviral treatment with an HIV-RNA < 50 cp/mL at the time of the switch to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG were retrospectively included in the analysis. Framingham risk score modification after 12 months from the switch such as lipid profile and body weight modification were assessed. The change from baseline to 12 months in mean cardiovascular risk and body weight in each of the STR’s group were assessed by means of Wilcoxon signed-rank test whereas a mixed regression model was used to assess variation in lipid levels. Results Five-hundred and sixty PLWH were switched to an STR regimen of whom 170 (30.4%) to TAF/FTC/EVG/cobi, 191 (34.1%) to TAF/FTC/RPV and 199 (35.5%) to ABC/3TC/DTG. No difference in the Framingham cardiovascular risk score was observed after 12 months from the switch in each of the STR’s groups. No significant overtime variation in mean total cholesterol levels from baseline to 12 months was observed for PLWH switched to ABC/3TC/DTG [200 (SD 38) mg/dl vs 201 (SD 35) mg/dl; p = 0.610] whereas a significant increment was observed in PLWH switched to TAF/FTC/EVG/cobi [192 (SD 34) mg/dl vs 208 (SD 40) mg/dl; p < 0.0001] and TAF/FTC/RPV [187 (SD 34) mg/dl vs 195 (SD 35) mg/dl; p = 0.027]. In addition, a significant variation in the mean body weight from baseline to 12 months was observed in PLWH switched to TAF/FTC/EVG/cobi [72.2 (SD 13.5) kilograms vs 74.6 (SD 14.3) kilograms; p < 0.0001] and TAF/FTC/RPV [73.4 (SD 11.6) kilograms vs 75.6 (SD 11.8) kilograms; p < 0.0001] whereas no difference was observed in those switched to ABC/3TC/DTG [71.5 (SD 12.8) kilograms vs 72.1 (SD 12.6) kilograms; p = 0.478]. Conclusion No difference in the cardiovascular risk after 1 year from the switch to these STRs were observed. PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch.

Sign in / Sign up

Export Citation Format

Share Document